Did you know? You can suggest edits to improve this peptide information.
Overview
What is Retatrutide?
Retatrutide (LY3437943) is a novel triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors. Phase III TRIUMPH-4 trial (Dec 2025) achieved 28.7% weight loss (71.2 lbs) at 68 weeks with 12mg dose - the highest recorded for any obesity medication. Currently in late-stage Phase III development by Eli Lilly with FDA approval expected 2026-2027.
Key Benefits
Triple hormone receptor activation provides superior weight loss (24.2%), improved glycemic control, and enhanced cardiovascular benefits compared to single or dual agonists
Mechanism of Action
Activates GLP-1 for appetite suppression, GIP for insulin sensitivity, and glucagon for increased energy expenditure and hepatic fat oxidation
Molecular Information
Weight
4,731.33 Da
Length
39 amino acids
Type
Triple GLP-1/GIP/glucagon agonist
Amino Acid Sequence:
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser
* C20 fatty acid conjugation with Aib residues for DPP-4 resistance
Pharmacokinetics
Research Indications
Superior Weight Reduction
Clinical trials demonstrate 17.5% at 24 weeks and 24.2% at 48 weeks - highest recorded for any obesity medication in development
Sustained Weight Management
Continuous weight loss throughout trials with no plateau reached at 48 weeks, suggesting greater long-term potential than current therapies
Triple Mechanism Obesity Treatment
Addresses obesity through appetite suppression, increased energy expenditure, and improved metabolic efficiency via three hormone pathways
Research Protocols
Disclaimer
These are commonly discussed research protocols and not medical advice. Consult a healthcare provider before use.
Timing
Administer on the same day each week for consistent hormone regulation. Can be taken with or without food due to subcutaneous administration.
Peptide Interactions
How to Reconstitute
Important
Use BAC water only. Avoid BAC saline (sodium chloride) - may cause precipitation or cloudiness. Refrigerate and use within 28 days.
Remove Retatrutide vial from refrigeration and allow to reach room temperature (15-20 minutes)
Clean vial top with alcohol swab and allow to air dry completely
Add calculated amount of bacteriostatic water slowly down the side of the vial to minimize foaming
Gently swirl the vial in circular motions - DO NOT shake vigorously as this may damage the peptide structure
Allow to fully dissolve (may take 2-3 minutes) - solution should be clear and colorless
Store reconstituted solution in refrigerator (2-8°C) and use within 28 days
Draw calculated dose using insulin syringe, inject subcutaneously into abdomen, thigh, or upper arm
Rotate injection sites weekly to prevent lipodystrophy and maintain absorption consistency
Quality Indicators
Pharmaceutical-grade white powder
Lyophilized Retatrutide should appear as a white to off-white powder with uniform texture and no discoloration
Proper cold chain maintenance
Reconstituted solution requires consistent refrigeration at 2-8°C with temperature monitoring
Clear reconstituted solution
Properly reconstituted Retatrutide forms a clear, colorless solution without particles, cloudiness, or precipitates
Stable extended half-life effects
Consistent appetite suppression and metabolic effects between weekly doses indicate proper potency
Source verification critical
Due to investigational status and high demand, counterfeit versions circulate - verify pharmaceutical-grade sourcing
Rapid tolerance or effectiveness loss
Genuine Retatrutide maintains efficacy long-term; rapid tolerance suggests degraded or counterfeit product
Unusual side effect profile
Effects significantly different from expected GI-predominant profile may indicate contaminated or incorrect product
What to Expect
- Week 1-2: Initial appetite suppression and mild GI effects as body adapts to triple hormone activation
- Week 2-4: Noticeable reduction in food cravings and portion sizes, early weight loss (2-5%)
- Week 4-8: Significant appetite control and steady weight loss (5-10%), improved glucose control if diabetic
- Week 8-16: Substantial weight reduction (10-18%) with enhanced energy expenditure and metabolic improvements
- Week 16-24: Major weight loss milestone (15-22%) with cardiovascular benefits and liver fat reduction
- Week 24-48: Maximum clinical efficacy (20-24.2%) with comprehensive metabolic improvements and sustained benefits
Side Effects & Safety
- Most common side effects are gastrointestinal (nausea 43%, diarrhea 33% at 12mg) - typically mild to moderate and dose-dependent
- NEW SIGNAL (Dec 2025): Dysesthesia (abnormal touch sensations) reported in 8.8-20.9% of participants at 9-12mg doses in TRIUMPH-4 trial
- Conservative start at 0.5mg weekly minimizes GI side effects (13% vs 73-94% at higher doses) - escalate gradually every 4 weeks
- Phase III discontinuation rates: 12.2% (9mg) and 18.2% (12mg) due to adverse events - correlated with baseline BMI
- Monitor for signs of pancreatitis (severe abdominal pain radiating to back) - discontinue immediately if suspected
- Heart rate increases are common, especially in first 24 weeks - monitor cardiovascular status regularly
- Contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN2 syndrome
- May cause rapid weight loss - some discontinuations due to perceived excessive weight loss
References
Phase III TRIUMPH-4 Trial - Eli Lilly (Dec 2025)
First successful Phase III trial in 445 adults with obesity and knee osteoarthritis. 12mg dose achieved 28.7% weight loss (71.2 lbs from 248.5 lb baseline) with 75.8% pain reduction. Discontinuation rates 12-18% due to GI effects; new dysesthesia signal in 8.8-20.9% of participants.
View Study (opens in new tab) →MASLD Substudy - Nature Medicine (2024)
Metabolic dysfunction-associated steatotic liver disease study showing dramatic liver fat reductions with normalization in over 90% of participants at highest doses.
View Study (opens in new tab) →TRIUMPH-Outcomes Cardiovascular Study (2024-2029)
Major cardiovascular outcomes trial assessing effects on MACE and kidney outcomes in participants with obesity and established cardiovascular or kidney disease.
View Study (opens in new tab) →Quick Start Guide
Community Poll
Question 1 of 10
What is your experience with this compound?
Community Insights
Self-reported by PepPedia users. Not clinical evidence. Health changes reflect all users, including those taking multiple compounds.
Was this helpful?
Your feedback helps us improve PepPedia